Close

BIO’s Jim Greenwood Meets with India’s PM Modi

Jan 13 2017
Delivers Message: India Must Protects Innovators’ Work Product

BIO Statement on Proposed Maryland Drug Pricing Legislation

Jan 10 2017
BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.

BIO CEO & Investor Conference Programming Announced

Dec 15 2016
BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to discover trends in life sciences, network with peers and potential partners and explore investment opportunities. Established and emerging publicly traded and select private biotech companies are the focus of the event.

BIO Applauds Senate Passage of the 21st Century Cures Act

Dec 7 2016
Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:

BIO Applauds House Passage of the 21st Century Cures Act

Nov 30 2016
Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

BIO Responds to GAO Report Declaring RFS Will Not Meet Goals

Nov 29 2016
BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels but we would observe that EPA has chilled investment in commercializing this technology.

BIO Welcomes EPA’s Final 2017 Renewable Fuel Standards

Nov 23 2016
The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and cellulosic biofuels.

BIO Statement on FDA Product Communications Hearing

Nov 9 2016
BIO President and CEO Jim Greenwood released the following statement today regarding the FDA’s hearing on product communications: “In the era of data-driven medicine, where all parties seek more, not less, information about the safety, effectiveness, and value of treatments, fostering informed communications among all stakeholders is critical.  We are in the midst of a transition to value-based healthcare – a transition that has the potential to improve the efficiency of the overall healthcare system. Earlier this year, BIO and its members endorsed a systemic set of principles and commitments in support of moving us toward a value-based system – the first major healthcare industry association to do so.  

BIO Patient and Health Advocacy Summit Hosts Over 300 Attendees from Wide Range of Health Care Organizations

Nov 4 2016
Over 200 diverse groups were represented at the November 3-4 meeting in Washington, D.C.

BIO Issues Call for Papers for 2017 World Congress on Industrial Biotechnology in Montréal

Nov 1 2016
BIO has officially issued a call to leaders from the biotechnology, bioenergy, chemical, consumer products manufacturing, and agricultural industries as well as academia and financial sectors industries to submit panel session proposals for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada.